Daily Cosmetic Research Analysis
Three studies advance cosmetic and dermatologic science across prevention, safety, and treatment. Visible-light protection with iron oxide added to SPF improved melasma outcomes in skin of color. Population biomonitoring in Korea showed a shift from BPA to BPS/BPF exposures with SES disparities, and a clinical study reported a 6‑week, multi-ingredient topical significantly reduced periorbital hyperpigmentation without adverse effects.
Summary
Three studies advance cosmetic and dermatologic science across prevention, safety, and treatment. Visible-light protection with iron oxide added to SPF improved melasma outcomes in skin of color. Population biomonitoring in Korea showed a shift from BPA to BPS/BPF exposures with SES disparities, and a clinical study reported a 6‑week, multi-ingredient topical significantly reduced periorbital hyperpigmentation without adverse effects.
Research Themes
- Visible light photoprotection for melasma and skin of color
- Endocrine disruptor substitution and cosmetic safety disparities
- Multi-target topical therapy for periorbital hyperpigmentation
Selected Articles
1. Photoprotection Efficacy of Sun Protection Factor and Iron Oxide Formulations in Diverse Skin With Melasma and Photodamage.
In women with FST III–VI, both SPF50 and SPF50+iron oxide improved skin quality over 12 weeks, but iron oxide conferred earlier benefits and superior radiance (L) outcomes in melasma (36% vs 0%). Patient-reported quality of life improved with SPF50+iron oxide.*
Impact: This study operationalizes visible-light protection in daily regimens and provides objective colorimetric and QoL evidence that iron oxide adds clinically meaningful benefit for melasma in skin of color.
Clinical Implications: Recommend visible-light protection (iron oxide–containing tinted products) in addition to high-SPF UV sunscreens for melasma, especially in skin of color; counsel on daily use indoors and outdoors.
Key Findings
- Both SPF50 and SPF50+iron oxide improved clinical appearance and instrumented colorimetric measures over 12 weeks.
- In melasma, 36% of participants on SPF50+iron oxide achieved superior radiance (L*) improvement vs 0% on SPF50 alone at week 12.
- Early improvements were observed at week 4 in photodamage (roughness) and overall healthy appearance with SPF50+iron oxide.
- Quality of life improved in melasma participants using SPF50+iron oxide.
Methodological Strengths
- Prospective 12-week evaluation with both clinical and objective colorimetric endpoints
- Inclusion of diverse Fitzpatrick skin types (III–VI) and subgroup analyses (melasma, photodamage)
Limitations
- Sample size not specified and randomization/blinding not reported
- Product adherence and confounders (makeup use, lighting) may influence outcomes
Future Directions: Conduct adequately powered randomized trials comparing SPF+iron oxide vs SPF alone across skin types, with standardized visible-light exposure metrics and long-term relapse outcomes in melasma.
Visible light (400-700nm) comprises 45% of the sunlight spectrum and can induce both immediate and persistent skin darkening, as well as worsen dyschromia, especially in the skin of color population. In a recent mini-zone study, we demonstrated that iron oxide (FeO)-containing formulations could protect skin from visible light-induced pigmentation in Fitzpatrick skin type (FST) IV individuals, while ultraviolet (UV) protection sunscreen SPF 50+ (sun protection factor) could not. To assess the benefit of adding FeO-containing foundation into real-life daily sun care routine in improving the appearance of photodamage and melasma, we evaluated the efficacy of two sun protection regimens (SPF50 alone and SPF50+FeO) in healthy women of FST III to VI for 12 weeks. Clinical evaluation and colorimetric measurement showed that both regimens significantly improved skin quality and overall appearance over 12 weeks compared to baseline. At week 4, the photodamage subgroup using SPF50+FeO showed early improvement over baseline in skin roughness (visual and tactile). The melasma subgroup using SPF50+FeO showed early improvement in overall healthy appearance. At week 12, although both groups showed improvement in colorimetric measurements (L*), the response was different: 36% of melasma participants in the SPF50+FeO group showed superior improvement in their skin radiance (L*) vs 0% in the SPF50 group. A self-assessment questionnaire revealed that SPF50+FeO enhanced the quality of life in participants with melasma. This study demonstrated the importance of including visible light protection into a daily sun care routine, especially for melasma: masking and improving existing conditions indoors and outdoors at the same time. J Drugs Dermatol. 2025;24(7):662-667. doi:10.36849/JDD.9240.
2. Changes of urinary bisphenol A and alternatives in Korea 2015-2020 and environmental disparities by socioeconomic status.
Among 8000 Korean adults (2015–2020), the urinary alternative-to-legacy bisphenol ratio rose markedly (0.09 to 0.73, 2017–2020), paralleling BPA regulations (e.g., bans in food containers, cosmetics, baby products). Higher-SES adults, particularly with university education, had significantly higher BP ratios (+70.1%).
Impact: Demonstrates population-level substitution from BPA to BPS/BPF and reveals SES-linked disparities, informing cosmetic and consumer product safety policies beyond “BPA-free” labeling.
Clinical Implications: Clinicians should counsel sensitive populations (e.g., reproductive, endocrine disorders) that “BPA-free” may mean substitution with other bisphenols; advocate for minimizing total bisphenol exposure and support policy efforts addressing environmental disparities.
Key Findings
- National survey of 8000 adults showed a sharp increase in (BPS+BPF)/BPA urinary ratio from 2017 to 2020 (0.09 to 0.73).
- Regulatory context included bans of BPA-containing consumer products, including cosmetics, food containers, and baby products.
- Higher education (university or above) was associated with a 70.1% higher BP ratio (95% CI: 1.8%, 182.9%) in 2020 after adjusting for age and sex.
Methodological Strengths
- Large, nationally representative biomonitoring dataset with survey weights
- Objective urinary biomarkers (BPA, BPS, BPF) and multivariable modeling of SES indices
Limitations
- Cross-sectional design cannot infer causality or health effects of substitution
- Spot urine measures subject to intra-individual variability; potential residual confounding
Future Directions: Longitudinal studies linking bisphenol substitution patterns with clinical endpoints, product-level measurements, and interventions to reduce total bisphenol exposure, focusing on equity.
BACKGROUND: Bisphenol A (BPA), mainly used as an ingredient for epoxy resins, is widely utilized in numerous daily necessities. However, due to its endocrine-disrupting property, many countries have regulated BPA usage in consumer products, which might motivate industries to prefer alternative chemicals such as bisphenol S (BPS) and bisphenol F (BPF). This study aimed to evaluate temporal changes in consumption patterns of bisphenol-containing products and evaluate whether such trend depended on socioeconomic status (SES). METHODS: We used data of general adults from the Korean National Environmental Health Survey (KoNEHS) 2015-2020 (n = 8000). Bisphenol exposures were measured by urinary concentrations of BPA, BPS, and BPF. A ratio of alternative-to-legacy bisphenol (BP ratio [(S + F)/A]) was then estimated as (BPS + BPF)/BPA. Associations between BP ratio and SES indices (each variable and a composite score of household income, residence area, occupation, and education) were examined using survey-weighted multiple linear regression models. RESULTS: During the study period of ...
3. Clinical Efficacy of a Novel Topical Formulation on Periorbital Dark Circles: An Objective Analysis.
A twice-daily, multi-ingredient topical applied for 6 weeks achieved a 47.94% average reduction in periorbital pigmentation intensity with no reported adverse effects, supported by instrumental assessments and standardized imaging.
Impact: Provides objective, clinically relevant evidence that a multi-target topical can substantially improve periorbital hyperpigmentation with an excellent safety profile over 6 weeks.
Clinical Implications: Consider multi-pathway topicals (niacinamide, arbutin, tranexamic acid, antioxidants) as first-line or adjunct therapy for periorbital dark circles, with counseling on realistic timelines (~6 weeks) and maintenance.
Key Findings
- Twice-daily application for 6 weeks reduced under-eye hyperpigmentation by an average of 47.94%.
- Instrumental quantitative assessments and standardized imaging corroborated clinical improvement.
- No adverse effects were observed; a separate safety study and cosmetic efficacy questionnaire were completed.
Methodological Strengths
- Objective instrumental assessments alongside standardized imaging
- Defined multi-ingredient formulation targeting pigmentary and aging pathways
Limitations
- Sample size not reported and likely single-arm without a vehicle control
- Short duration (6 weeks) without long-term relapse data
Future Directions: Randomized, vehicle-controlled trials stratified by etiologic subtype (vascular/pigmentary/structural) with longer follow-up and patient-reported outcomes.
BACKGROUND: Hyperpigmentation and periorbital dark circles remain challenging dermatological concerns due to their multifactorial etiology, including vascular, pigmentary, and structural components. This study evaluates the efficacy of a novel multi-action topical formulation designed to target hyperpigmentation and skin aging through a synergistic blend of active ingredients. OBJECTIVE: To assess the objective and clinical effects of a dermatological composition containing niacinamide, arbutin, tranexamic acid, ubiquinone, a DHEA-like component, curcuma oily extract, and marine exopolysaccharides on periorbital hyperpigmentation and skin quality. METHODS: Subjects with visible under-eye dark circles applied the formulation twice daily over a treatment period of 6 weeks. The evaluation included instrumental quantitative assessments of skin pigmentation along with standardized imaging. A separate safety study and cosmetic efficacy questionnaire of patient experience were completed. RESULTS: The formulation demonstrated statistically significant improvements in pigmentation intensity. The twice daily use of the under-eye serum resulted in an average overall reduction in under-eye hyperpigmentation of 47.94%, with no adverse effects observed. CONCLUSION: This novel topical composition offers a safe and effective multi-targeted approach for improving periorbital hyperpigmentation and promoting overall skin rejuvenation. The synergistic action of its active components supports its use in clinical and aesthetic dermatology for the treatment of dark circles and age-related changes.